Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

September 18, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 22, 2017

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

Cenicriviroc

CVC 150 mg, administered orally once daily and taken every morning with food.

DRUG

Placebo

Placebo administered orally once daily and taken every morning with food.

Trial Locations (91)

1070

Brussels

1200

Brussels

2605

Garran

2650

Edegem

3000

Leuven

3004

Melbourne

3084

Heidelberg

Heidelberg

3168

Clayton

4029

Herston

5000

Adelaide

5042

Bedford Park

6000

Perth

10029

New York

13353

Berlin

14201

Buffalo

20089

Rozzano

20122

Milan

20246

Hamburg

20815

Chevy Chase

21093

Lutherville

21202

Baltimore

21287

Baltimore

23298

Richmond

23538

Lübeck

27103

Winston-Salem

27612

Raleigh

27710

Durham

28007

Madrid

30625

Hanover

31059

Toulouse

33136

Miami

33604

Pessac

33606

Tampa

34295

Montpellier

35043

Marburg

36305

Dothan

37421

Chattanooga

38138

Germantown

38801

Tupelo

39232

Flowood

40138

Bologna

40202

Louisville

45249

Cincinnati

48109

Ann Arbor

49100

Angers

50937

Cologne

52074

Aachen

54500

Vandœuvre-lès-Nancy

55114

Saint Paul

60612

Chicago

69120

Heidelberg

69317

Lyon

70112

New Orleans

75012

Paris

75651

Paris

77030

Houston

78215

San Antonio

78233

Live Oak

San Antonio

78234

Houston

80120

Littleton

84132

Salt Lake City

85054

Phoenix

85712

Tucson

90127

Palermo

92120

San Diego

92161

San Diego

92377

Rialto

94115

San Francisco

94800

Villejuif

98104

Seattle

02114

Boston

01655

Worcester

Unknown

Jackson

Shatin

04103

Leipzig

41-500

Chorzów

Mysłowice

91-347

Lodz

35-055

Rzeszów

50-349

Wroclaw

03010

Alicante

08026

Barcelona

08035

Barcelona

08036

Barcelona

PO6 3LY

Portsmouth

E1 1BB

London

NW3 2QR

London

NE7 7ND

Newcastle

NG7 2UH

Nottingham

All Listed Sponsors
lead

Tobira Therapeutics, Inc.

INDUSTRY

NCT02217475 - Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis | Biotech Hunter | Biotech Hunter